,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,955 Chesterbrook Boulevard,Suite 110,Chesterbrook,PA,19087,United States,610 354 8840,https://www.trevena.com,Biotechnology,Healthcare,"Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.",35,"{'maxAge': 1, 'name': 'Ms. Carrie L. Bourdow', 'age': 59, 'title': 'Pres, CEO & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 1002005, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.696,0.7014,0.68,0.7084,0.696,0.7014,0.68,0.7084,0.0,1.905255,-1.2962962,139626,139626,653598,3328900,3328900,0.682,0.7005,1400,900,9598470,0.537,5.125,3.7074044,0.90306,1.186685,0.0,0.0,USD,1577497,0.0,13607790,13712100,367515,374930,1690761600,1693440000,0.026800001,0.01095,0.08814,4.22,0.027,0.713,0.9817672,1672444800,1703980800,1688083200,-38131000,-4.39,-0.54,0.609,-0.038,NCM,EQUITY,TRVN,TRVN,"Trevena, Inc.","Trevena, Inc.",1391178600,America/New_York,EDT,-14400000,0.7,9.0,4.0,6.5,6.5,2.0,buy,2,28097000,2.049,-41079000,20076000,3.437,4.033,2589000,205.234,0.286,-0.49942002,-1.6678799,-3436000,-24197876,-39394000,-0.08497,0.0,-15.99691,USD,
1,955 Chesterbrook Boulevard,Suite 110,Chesterbrook,PA,19087,United States,610 354 8840,https://www.trevena.com,Biotechnology,Healthcare,"Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.",35,"{'maxAge': 1, 'name': 'Mr. Barry  Shin', 'age': 50, 'title': 'Sr. VP & CFO', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 670025, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.696,0.7014,0.68,0.7084,0.696,0.7014,0.68,0.7084,0.0,1.905255,-1.2962962,139626,139626,653598,3328900,3328900,0.682,0.7005,1400,900,9598470,0.537,5.125,3.7074044,0.90306,1.186685,0.0,0.0,USD,1577497,0.0,13607790,13712100,367515,374930,1690761600,1693440000,0.026800001,0.01095,0.08814,4.22,0.027,0.713,0.9817672,1672444800,1703980800,1688083200,-38131000,-4.39,-0.54,0.609,-0.038,NCM,EQUITY,TRVN,TRVN,"Trevena, Inc.","Trevena, Inc.",1391178600,America/New_York,EDT,-14400000,0.7,9.0,4.0,6.5,6.5,2.0,buy,2,28097000,2.049,-41079000,20076000,3.437,4.033,2589000,205.234,0.286,-0.49942002,-1.6678799,-3436000,-24197876,-39394000,-0.08497,0.0,-15.99691,USD,
2,955 Chesterbrook Boulevard,Suite 110,Chesterbrook,PA,19087,United States,610 354 8840,https://www.trevena.com,Biotechnology,Healthcare,"Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.",35,"{'maxAge': 1, 'name': 'Dr. Mark A. Demitrack', 'age': 64, 'title': 'Sr. VP & Chief Medical Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 690316, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.696,0.7014,0.68,0.7084,0.696,0.7014,0.68,0.7084,0.0,1.905255,-1.2962962,139626,139626,653598,3328900,3328900,0.682,0.7005,1400,900,9598470,0.537,5.125,3.7074044,0.90306,1.186685,0.0,0.0,USD,1577497,0.0,13607790,13712100,367515,374930,1690761600,1693440000,0.026800001,0.01095,0.08814,4.22,0.027,0.713,0.9817672,1672444800,1703980800,1688083200,-38131000,-4.39,-0.54,0.609,-0.038,NCM,EQUITY,TRVN,TRVN,"Trevena, Inc.","Trevena, Inc.",1391178600,America/New_York,EDT,-14400000,0.7,9.0,4.0,6.5,6.5,2.0,buy,2,28097000,2.049,-41079000,20076000,3.437,4.033,2589000,205.234,0.286,-0.49942002,-1.6678799,-3436000,-24197876,-39394000,-0.08497,0.0,-15.99691,USD,
3,955 Chesterbrook Boulevard,Suite 110,Chesterbrook,PA,19087,United States,610 354 8840,https://www.trevena.com,Biotechnology,Healthcare,"Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.",35,"{'maxAge': 1, 'name': 'Dr. Howard A. Rockman M.D.', 'title': 'Scientific Founder, Consultant and Member of Scientific Advisory Board', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.696,0.7014,0.68,0.7084,0.696,0.7014,0.68,0.7084,0.0,1.905255,-1.2962962,139626,139626,653598,3328900,3328900,0.682,0.7005,1400,900,9598470,0.537,5.125,3.7074044,0.90306,1.186685,0.0,0.0,USD,1577497,0.0,13607790,13712100,367515,374930,1690761600,1693440000,0.026800001,0.01095,0.08814,4.22,0.027,0.713,0.9817672,1672444800,1703980800,1688083200,-38131000,-4.39,-0.54,0.609,-0.038,NCM,EQUITY,TRVN,TRVN,"Trevena, Inc.","Trevena, Inc.",1391178600,America/New_York,EDT,-14400000,0.7,9.0,4.0,6.5,6.5,2.0,buy,2,28097000,2.049,-41079000,20076000,3.437,4.033,2589000,205.234,0.286,-0.49942002,-1.6678799,-3436000,-24197876,-39394000,-0.08497,0.0,-15.99691,USD,
4,955 Chesterbrook Boulevard,Suite 110,Chesterbrook,PA,19087,United States,610 354 8840,https://www.trevena.com,Biotechnology,Healthcare,"Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.",35,"{'maxAge': 1, 'name': 'Mr. Joel  Solomon', 'title': 'VP, Gen. Counsel & Chief Compliance Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.696,0.7014,0.68,0.7084,0.696,0.7014,0.68,0.7084,0.0,1.905255,-1.2962962,139626,139626,653598,3328900,3328900,0.682,0.7005,1400,900,9598470,0.537,5.125,3.7074044,0.90306,1.186685,0.0,0.0,USD,1577497,0.0,13607790,13712100,367515,374930,1690761600,1693440000,0.026800001,0.01095,0.08814,4.22,0.027,0.713,0.9817672,1672444800,1703980800,1688083200,-38131000,-4.39,-0.54,0.609,-0.038,NCM,EQUITY,TRVN,TRVN,"Trevena, Inc.","Trevena, Inc.",1391178600,America/New_York,EDT,-14400000,0.7,9.0,4.0,6.5,6.5,2.0,buy,2,28097000,2.049,-41079000,20076000,3.437,4.033,2589000,205.234,0.286,-0.49942002,-1.6678799,-3436000,-24197876,-39394000,-0.08497,0.0,-15.99691,USD,
5,955 Chesterbrook Boulevard,Suite 110,Chesterbrook,PA,19087,United States,610 354 8840,https://www.trevena.com,Biotechnology,Healthcare,"Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.",35,"{'maxAge': 1, 'name': 'Mr. Michael  Catalano', 'title': 'VP of Marketing', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.696,0.7014,0.68,0.7084,0.696,0.7014,0.68,0.7084,0.0,1.905255,-1.2962962,139626,139626,653598,3328900,3328900,0.682,0.7005,1400,900,9598470,0.537,5.125,3.7074044,0.90306,1.186685,0.0,0.0,USD,1577497,0.0,13607790,13712100,367515,374930,1690761600,1693440000,0.026800001,0.01095,0.08814,4.22,0.027,0.713,0.9817672,1672444800,1703980800,1688083200,-38131000,-4.39,-0.54,0.609,-0.038,NCM,EQUITY,TRVN,TRVN,"Trevena, Inc.","Trevena, Inc.",1391178600,America/New_York,EDT,-14400000,0.7,9.0,4.0,6.5,6.5,2.0,buy,2,28097000,2.049,-41079000,20076000,3.437,4.033,2589000,205.234,0.286,-0.49942002,-1.6678799,-3436000,-24197876,-39394000,-0.08497,0.0,-15.99691,USD,
6,955 Chesterbrook Boulevard,Suite 110,Chesterbrook,PA,19087,United States,610 354 8840,https://www.trevena.com,Biotechnology,Healthcare,"Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.",35,"{'maxAge': 1, 'name': 'Mr. Robert T. Yoder', 'age': 56, 'title': 'Sr. VP, Chief Bus. Officer & Head of Commercial Operations', 'yearBorn': 1966, 'fiscalYear': 2019, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.696,0.7014,0.68,0.7084,0.696,0.7014,0.68,0.7084,0.0,1.905255,-1.2962962,139626,139626,653598,3328900,3328900,0.682,0.7005,1400,900,9598470,0.537,5.125,3.7074044,0.90306,1.186685,0.0,0.0,USD,1577497,0.0,13607790,13712100,367515,374930,1690761600,1693440000,0.026800001,0.01095,0.08814,4.22,0.027,0.713,0.9817672,1672444800,1703980800,1688083200,-38131000,-4.39,-0.54,0.609,-0.038,NCM,EQUITY,TRVN,TRVN,"Trevena, Inc.","Trevena, Inc.",1391178600,America/New_York,EDT,-14400000,0.7,9.0,4.0,6.5,6.5,2.0,buy,2,28097000,2.049,-41079000,20076000,3.437,4.033,2589000,205.234,0.286,-0.49942002,-1.6678799,-3436000,-24197876,-39394000,-0.08497,0.0,-15.99691,USD,
7,955 Chesterbrook Boulevard,Suite 110,Chesterbrook,PA,19087,United States,610 354 8840,https://www.trevena.com,Biotechnology,Healthcare,"Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.",35,"{'maxAge': 1, 'name': 'Ms. Patricia M. Drake', 'age': 56, 'title': 'Sr. VP & Chief Commercial Officer', 'yearBorn': 1966, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.696,0.7014,0.68,0.7084,0.696,0.7014,0.68,0.7084,0.0,1.905255,-1.2962962,139626,139626,653598,3328900,3328900,0.682,0.7005,1400,900,9598470,0.537,5.125,3.7074044,0.90306,1.186685,0.0,0.0,USD,1577497,0.0,13607790,13712100,367515,374930,1690761600,1693440000,0.026800001,0.01095,0.08814,4.22,0.027,0.713,0.9817672,1672444800,1703980800,1688083200,-38131000,-4.39,-0.54,0.609,-0.038,NCM,EQUITY,TRVN,TRVN,"Trevena, Inc.","Trevena, Inc.",1391178600,America/New_York,EDT,-14400000,0.7,9.0,4.0,6.5,6.5,2.0,buy,2,28097000,2.049,-41079000,20076000,3.437,4.033,2589000,205.234,0.286,-0.49942002,-1.6678799,-3436000,-24197876,-39394000,-0.08497,0.0,-15.99691,USD,
